仙乐健康(300791) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 100.23% to CNY 61,797,888.82 for the quarter[10] - Operating revenue for the quarter reached CNY 537,574,510.57, representing a 40.58% increase year-on-year[10] - Basic earnings per share rose by 30.77% to CNY 0.51[10] - The company reported a net profit margin of 11.48% for the quarter[10] - The company's net profit for the current period is ¥61,797,822.47, compared to ¥30,863,884.29 in the previous period, representing a growth of approximately 100.5%[70] - Total operating revenue for the current period is ¥357,587,611.10, an increase of 34.1% from ¥266,589,016.38 in the previous period[74] - The total profit for the current period was ¥221,159,465.66, compared to ¥130,557,268.67 in the previous period, marking a significant increase of 69.3%[81] - The company reported a net profit margin of approximately 11.0% for the current period, compared to 10.4% in the previous period, showing improved profitability[70] Assets and Liabilities - Total assets increased by 11.77% to CNY 2,636,774,007.51 compared to the end of the previous year[10] - Accounts receivable increased by 37.88% to RMB 257,448,001.42 due to higher sales during the reporting period[22] - Inventory rose by 34.43% to RMB 274,649,729.47, reflecting increased sales[22] - Construction in progress surged by 74.93% to RMB 160,902,723.31, attributed to significant investment in the Ma'anshan production base[22] - The company's total liabilities as of September 30, 2020, were CNY 525,391,352.70, compared to CNY 414,008,532.79 at the end of 2019, reflecting an increase of approximately 27%[52] - The total liabilities of the company were CNY 414 million as of December 31, 2019, with no changes reported[110] - The company's total assets increased to ¥2,331,133,120.29 from ¥2,196,585,691.95, representing a growth of 6.1%[62] Cash Flow - Net cash flow from operating activities increased by 49.14% to CNY 123,013,388.38[10] - The net cash flow from financing activities dropped by 106.03% to RMB -56,544,812.42, compared to RMB 937,294,016.72 in the same period last year[24] - Operating cash flow from operating activities increased to ¥233,720,210.46, up from ¥193,186,287.82, representing a growth of approximately 21.0%[91] - Cash inflow from investment activities totaled ¥2,486,368,066.96, significantly higher than the previous year's ¥11,328,824.35[94] - Cash paid to employees increased to ¥228,995,675.13 from ¥200,222,152.79, reflecting a rise of approximately 14.4%[91] Shareholder Information - The total number of shareholders at the end of the reporting period was 6,185[14] - The top shareholder, Chen Qiong, holds 43.20% of the shares, totaling 51,840,000 shares[14] - The company approved a stock incentive plan, granting 686,500 shares at a price of RMB 30.20 per share to 49 individuals[29] Government Support and Investments - The company received government subsidies amounting to CNY 24,282,279.23 during the reporting period[12] - The company plans to invest RMB 20,001 million in a health industry investment partnership, with an initial contribution of RMB 10,000 million[34] Research and Development - Research and development expenses for the quarter were ¥18,558,523.34, compared to ¥16,355,015.32, indicating a 13.5% increase[66] - Research and development expenses for the current period are ¥15,019,923.30, slightly up from ¥14,260,315.14, indicating a focus on innovation[74] - The company reported a significant increase in retained earnings, which reached ¥851,697,279.38, up from ¥749,155,139.44, a growth of 13.7%[62] Compliance and Governance - The company has not reported any overdue commitments from major shareholders or related parties during the reporting period[37] - There were no violations regarding external guarantees during the reporting period[40] - The company has completed the registration of changes in registered capital and obtained a new business license as of August 17, 2020[36]